Preventing Complications in Cleft Palate Repair With Antibiotics
Launched by JOSEPH LOSEE · Sep 24, 2008
Trial Information
Current as of July 22, 2025
Completed
Keywords
ClinConnect Summary
During the initial clinical visit, the clinical diagnosis of a cleft secondary palate or submucous cleft will be made. Other associated clinical findings such as unilateral/bilateral cleft lip, unilateral/bilateral cleft primary palate, Veau cleft palate classification, and associated syndromic diagnosis will be recorded. The severity of the cleft palate will be documented by measuring the width of the cleft and the hard-soft palate juncture. The patients will proceed through the standardized cleft treatment protocol as mandated by their specific anatomic findings. These include possible na...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children diagnosed as having cleft palates undergoing palatoplasty between the ages of 3 months and 18 years will be included in this study. Palatoplasty is the current standard of care in the sequence of treatment for cleft secondary palates. Pediatric plastic surgeons work primarily with children, and have undergone extensive training during their residencies and pediatric surgical fellowships to do so. Children will be evaluated initially at the Cleft-Craniofacial Center at the Children's Hospital of Pittsburgh of UPMC, which is set up to accommodate children of all ages and their families. Approximately 300 children will be required to contribute to a meaningful analysis.
- Exclusion Criteria:
- • All patients requiring prophylactic antibiotics for spontaneous bacterial endocarditis, with documented allergic reactions to the ampicillin-sulbactam, and with known immunodeficiencies or immunodeficiency associated syndromes, such as the 22q chromosomal deletion, will be excluded from study participation.
- • Selection will be based on the parent's willingness to allow their child to participate in the study.
- • Children already receiving antibiotics at the time of their surgery will be evaluated distinctly, though they will not be included in the antibiotic or the placebo groups
About Joseph Losee
Joseph Losee is a distinguished clinical trial sponsor known for his commitment to advancing medical research and improving patient outcomes. With a strong background in clinical medicine and a focus on innovative therapeutic strategies, Joseph Losee oversees a range of clinical trials designed to evaluate the efficacy and safety of novel interventions. His leadership emphasizes rigorous scientific methodology, ethical standards, and collaboration with multidisciplinary teams, ensuring that each study contributes valuable insights to the medical community. Through his efforts, Joseph Losee aims to bridge the gap between research and clinical practice, ultimately enhancing the quality of care for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Joseph Losee, MD
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials